Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: A systematic review and multiple treatment meta-analysis

References

• Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr, Doll R. Mortality from smoking worldwide. Br Med Bull. 1996;52:12–21.
   PubMed Web of Science ®Google Scholar
• Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ. 1994;309:901–11.
   PubMed Web of Science ®Google Scholar
• Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet. 2007;370:2044–53.
   PubMed Web of Science ®Google Scholar
• Wu P, Wilson K, Dimoulas P, Mills EJ. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health. 2006;6:300.
   PubMed Web of Science ®Google Scholar
• Meade MO, Cook RJ, Guyatt GH, Groll R, Kachura JR, Bedard M, . Interobserver variation in interpreting chest radiographs for the diagnosis of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2000;161:85–90.
   PubMed Web of Science ®Google Scholar
• Eisenberg MJ, Filion KB, Yavin D, Belisle P, Mottillo S, Joseph L, . Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ. 2008;179:135–44.
   PubMed Web of Science ®Google Scholar
• Hays JT, Ebbert JO. Varenicline for tobacco dependence. N Engl J Med. 2008;359:2018–24.
   PubMed Web of Science ®Google Scholar
• Hays JT, Ebbert JO. Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits. CNS Drugs. 2003;17:71–83.
   PubMed Web of Science ®Google Scholar
• Mills EJ, Wu P, Spurden D, Ebbert JO, Wilson K. Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis. Harm Reduct J. 2009;6:25.
   PubMed Web of Science ®Google Scholar
• Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, . Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47–55.
   PubMed Web of Science ®Google Scholar
• Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, . Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006;166:1561–8.
   PubMed Web of Science ®Google Scholar
• Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR. Varenicline Phase 3 Study Group. http://www.ncbi.nlm.nih.gov/pubmed/16820547 Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296: 56–63.
   PubMed Web of Science ®Google Scholar
• Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz N, Curry SJ, . Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service; 2008, http://www.ahrq.gov/clinic/tobacco/treating_tobacco_use08.pdf.
   Google Scholar
• Ruth KJ, Neaton JD. Evaluation of two biological markers of tobacco exposure. MRFIT Research Group. Prev Med. 1991;20:574–89.
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
   PubMed Web of Science ®Google Scholar
• Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23: 3105–24.
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683–91.
   PubMed Web of Science ®Google Scholar
• Walter SD. Choice of effect measure for epidemiological data. J Clin Epidemiol. 2000;53:931–9.
   PubMed Web of Science ®Google Scholar
• Perng RP, Hsieh WC, Chen YM, Lu CC, Chiang SJ. Randomized, double-blind, placebo-controlled study of transdermal nicotine patch for smoking cessation. J Formos Med Assoc. 1998;97:547–51.
   Google Scholar
• Mills EJ, Ghement I, O’Regan C, Thorlund K. Estimating the power of indirect comparisons: a simulation study. PLOS One. 2011;6:e16237.
   PubMed Web of Science ®Google Scholar
• Mills EJ, Bansback N, Ghement I, Thorlund K, Kelly S, Puhan M, . Multiple treatment comparison meta-analyses: a step forward into complexity. Clin Epidemiol. 2011;3:1–10.
   Google Scholar
• O’Regan C, Ghement I, Eyawo O, Guyatt GH, Mills EJ. Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison. Trials. 2009;10:86.
   Google Scholar
• Song F, Harvey I, Lilford RAdjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol. 2008; 61:455–63.
   PubMed Web of Science ®Google Scholar
• Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008:CD000146.
   Google Scholar
• Ebbert JO, Hays JT, Hurt RD. Combination pharmacotherapy for stopping smoking: what advantages does it offer?Drugs. 2010;70:643–50.
   PubMed Web of Science ®Google Scholar
• Ebbert JO, Burke MV, Hays JT, Hurt RDCombination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res. 2009;11:572–6.
   PubMed Web of Science ®Google Scholar